Antibody response of heterologous vs homologous mRNA vaccine boosters against the SARS-CoV-2 Omicron variant: interim results from the PRIBIVAC study, A Randomized Clinical Trial.

Xuan Ying PohChee Wah TanI Russel LeeJean-Marc ChavatteSiew-Wai FongTessa PrinceCatherine HartleyAileen Ying-Yan YeohSuma RaoPo Ying ChiaSean Wx OngTau Hong LeeSapna P SadaranganiRay Jh LinClarissa LimJefanie TeoDaniel Rx LimWanni ChiaJulian A HiscoxLisa F P NgEe Chee RenRaymond Tp LinLaurent ReniaDavid Chien LyeLin-Fa WangBarnaby E Young

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022)

Heterologous mRNA-1273 booster vaccination induced a stronger neutralizing response against the Omicron variant in older individuals compared with homologous BNT123b2.

Keyphrases

sars cov
dna repair
dna damage
binding protein
high glucose
physical activity
diabetic rats
saccharomyces cerevisiae
respiratory syndrome coronavirus
community dwelling
coronavirus disease